menu
    • menu
    [{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lanraplenib

    Menu

    Lanraplenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

                            Details : Lanraplenib (Lanra) has demonstrated favorable pharmacokinetic (PK), pharmacodynamic (PD) and safety in more than 250 trial participants, including healthy volunteers and patients with autoimmune diseases.

                            Brand Name : Lanra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2022

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilte...

                            Details : Lanra (lanraplenib) is the company’s next-generation spleen tyrosine kinase (SYK) inhibitor. In addition to lanraplenib, Kronos Bio is also evaluating its lead investigational SYK inhibitor, entospletinib, in the Phase 3 patients with NPM1-mutated AML.

                            Brand Name : Lanra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Kronos Bio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kronos Gets FDA Clearance Investigational NDA for Lanraplenib for Treatment of Patient with Leukemia AML

                            Details : The first stage will evaluate initial safety, PK and anti-leukemic activity of escalating once-daily doses of LANRA in combination with the standard approved dose of gilteritinib.

                            Brand Name : Lanra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2021

                            Lead Product(s) : Lanraplenib,Gilteritinib Fumarate

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth